Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, today announced the publication of the phase 2b TULIP study results with its CETP inhibitor, TA-8995, in the Lancet.The peer-reviewed article is entitled “Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial”. Please follow this link to Dezima Pharma’s article in The Lancet.